Scribd
Upload
18 views1 page

Cyclosporine A Effects in STEMI Trial

Cyclosporine A was studied in patients with ST-segment elevation myocardial infarction (STEMI) who underwent reperfusion therapy in the CYCLE trial. The trial found no significant differences between the cyclosporine A and control groups in the primary endpoints of ST-segment resolution or biomarkers of cardiac injury. Specifically, the rates of at least 70% ST-segment resolution, levels of cardiac troponins and creatine kinase, and left ventricular ejection fraction were all similar between the two groups.

Uploaded by

Tania
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
18 views1 page

Cyclosporine A Effects in STEMI Trial

Cyclosporine A was studied in patients with ST-segment elevation myocardial infarction (STEMI) who underwent reperfusion therapy in the CYCLE trial. The trial found no significant differences between the cyclosporine A and control groups in the primary endpoints of ST-segment resolution or biomarkers of cardiac injury. Specifically, the rates of at least 70% ST-segment resolution, levels of cardiac troponins and creatine kinase, and left ventricular ejection fraction were all similar between the two groups.

Uploaded by

Tania
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

370 Ottani et al. JACC VOL. 67, NO.

4, 2016

Cyclosporine A in Reperfused STEMI FEBRUARY 2, 2016:365–74

CE NTR AL IL LUSTR ATI ON Cyclosporine in Reperfused STEMI: Effects on Primary and Secondary Endpoints in the CYCLE Trial

Ottani, F. et al. J Am Coll Cardiol. 2016; 67(4):365–74.

Effects of cyclosporine A on primary and selected secondary endpoints in the CYCLE trial in all patients (shaded area) and by infarct site. (A) Incidence
of $70% ST-segment resolution; (B) plasma concentrations of hs-cTnT on day 4; (C) LVEF on day 4; (D) percentage of LV A/D segments on day 4.
ANOVA ¼ analysis of variance; CsA ¼ cyclosporine A; CYCLE ¼ CYCLosporinE A in Reperfused Acute Myocardial Infarction; hs-cTnT ¼ high-sensitivity
cardiac troponin T; LV A/D ¼ left ventricular akinetic/dyskinetic; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; STEMI ¼ ST-segment
elevation myocardial infarction.

respectively, 268 (151 to 446) and 250 (141 to 444) groups (p for treatment ¼ 0.16). The percentage of
ng,ml1,h in CsA and controls (p ¼ 0.66). The LV A/D segments was higher in anterior MIs, and
results of the centrally assayed hs-cTnT were decreased significantly from day 4 to month 6,
consistent with those of cardiac troponins and CK in although there was no difference between the 2 study
terms of peak levels (Online Figure 2) and time groups (p ¼ 0.61) (Central Illustration, panels C and D,
courses (Online Figure 3), assayed locally, and Online Table 2).
normalized by the upper limit of normal for each Consistent with the findings on ST-segment reso-
laboratory. Analysis of the echocardiographic assess- lution, myocardial blush grades 2 to 3 at the final
ment of LV remodeling was in full agreement with angiography (a marker of successful reperfusion) did
these biomarkers with respect to CsA effects. The not show any difference by study treatment: 77.3%
LVEF was lower, as expected in anterior MIs, but in CsA and 80.8% in controls (p ¼ 0.82) (Online
there was no difference between the CsA and control Table 1).

You might also like